Tirzepatide vs Semaglutide: Which One Works Better?

Semaglutide is a single-agonist medication that mimics GLP-1, a hormone released after eating that slows gastric emptying, signals fullness to the brain, and improves insulin secretion. It is sold as Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral). Tirzepatide is a dual agonist that mimics both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Hitting two incretin pathways appears to amplify appetite suppression and improve metabolic efficiency. It is sold as Mounjaro (diabetes) and Zepbound (weight loss). Both are once-weekly subcutaneous injections taken at home with a pre-filled pen, titrated up over months to manage side effects.

The clearest answer comes from SURMOUNT-5, the first direct head-to-head trial, published in the New England Journal of Medicine in 2025. Adults with obesity who did not have diabetes were randomized to maximum-tolerated doses of either medication for 72 weeks. Tirzepatide produced a mean weight loss of 20.2%, compared to 13.7% for semaglutide. About 32% of tirzepatide users lost at least a quarter of their body weight, vs 16% on semaglutide. In the original SURMOUNT-1 trial, tirzepatide produced up to 22.5% weight loss at the 15 mg dose. The STEP 1 semaglutide trial showed average loss of 14.9% at 2.4 mg. Real-world results tend to run a few percentage points lower than trial averages.

Semaglutide currently has the stronger cardiovascular outcomes evidence. The SELECT trial (NEJM, 2023) showed a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) over about 40 months in adults with obesity and pre-existing heart disease who did not have diabetes — a landmark finding that led to an FDA label update. Tirzepatide has strong metabolic data from SURMOUNT-MMO and SURPASS but no completed CV-outcomes trial of equivalent scope yet, though one is ongoing. Both medications meaningfully improve A1c, blood pressure, triglycerides, and liver fat (MASH). For someone with established cardiovascular disease, semaglutide may currently be the more evidence-backed choice.

Side-effect profiles overlap heavily because both target GLP-1. The most common are nausea, constipation, diarrhea, vomiting, fatigue, and indigestion, especially during dose escalation. In SURMOUNT-5, 44% of tirzepatide users reported nausea vs 40% on semaglutide. Sulfur burps and intense food aversion seem slightly more reported anecdotally on tirzepatide, possibly due to GIP's effect on gastric emptying. Semaglutide users sometimes report stronger psychiatric side effects like flat mood, though large analyses have not confirmed an increased depression risk. Rare but serious risks for both include pancreatitis, gallbladder disease, and worsening diabetic retinopathy. Both carry a boxed warning for medullary thyroid carcinoma based on rodent data.

Both list around $1,000–$1,350 per month without insurance in the U.S. Insurance coverage varies wildly — most plans cover the diabetes versions (Ozempic, Mounjaro) for people with type 2 diabetes, while coverage for the obesity versions (Wegovy, Zepbound) is improving but still inconsistent. Eli Lilly's LillyDirect sells single-dose Zepbound vials at lower prices (~$349–$499/month depending on dose) for self-pay patients. Compounded versions exist but the FDA's drug-shortage list for both medications has been resolved, narrowing the legal pathway for compounding. Always verify a compounding pharmacy is state-licensed and using FDA-approved active ingredients.

There is no universally 'better' medication — there's the better medication for you. Tirzepatide tends to win on raw weight-loss percentage and may be preferable for higher BMIs or significant insulin resistance. Semaglutide has the stronger cardiovascular dataset and is FDA-approved for cardiovascular risk reduction. Switching between the two is common: many people start on one based on insurance and switch if response stalls or side effects don't improve. Discuss with your provider: your BMI, cardiovascular history, diabetes status, kidney function, prior gallbladder issues, mental health history, and budget. The best medication is the one you can actually take consistently.